NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth between 16% and 24%, down from 26% in 2024 but aligning with analysts' expectations of around 20%.
Novo Nordisk faces increasing competition from Eli Lilly (NYSE:LLY), a key rival in the weight-loss drug market. Despite this, the company reported strong fourth-quarter results, with operating profit surging 37% to 36.7 billion Danish crowns ($5.12 billion), surpassing analysts' estimates of 33.6 billion. For 2025, the company expects operating profit growth between 19% and 27%, compared to last year's 26%.
Wegovy sales more than doubled in Q4, reaching 19.9 billion crowns, up from 9.6 billion a year earlier and exceeding the 17.3 billion recorded in Q3. The sustained demand underscores the drug’s strong market position, although future growth is expected to decelerate.
As the weight-loss drug market evolves, Novo Nordisk continues to navigate supply constraints and rising competition. Investors remain focused on the company’s long-term outlook as it balances expansion efforts with growing market challenges.
